"HLA-A2 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
| Descriptor ID |
D015789
|
| MeSH Number(s) |
D12.776.395.550.489.400.020 D12.776.543.550.439.400.020 D23.050.301.500.100.400.020 D23.050.301.500.450.370.020 D23.050.705.552.100.400.020 D23.050.705.552.450.370.374
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HLA-A2 Antigen".
Below are MeSH descriptors whose meaning is more specific than "HLA-A2 Antigen".
This graph shows the total number of publications written about "HLA-A2 Antigen" by people in this website by year, and whether "HLA-A2 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 2 | 3 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HLA-A2 Antigen" by people in Profiles.
-
Gene editing of CD3 epsilon to redirect regulatory T?cells for adoptive T?cell transfer. Mol Ther. 2025 Mar 05; 33(3):997-1013.
-
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 03; 31(3):529-542.
-
Tumor-associated antigen prediction using a single-sample gene expression state inference algorithm. Cell Rep Methods. 2024 Nov 18; 4(11):100906.
-
Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy. 2024 Nov; 26(11):1331-1340.
-
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023 08 01; 33(4):332-337.
-
Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma In Situ. Cancer Prev Res (Phila). 2023 06 01; 16(6):333-341.
-
Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy. 2021 09; 23(9):793-798.
-
Global analysis of shared T?cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity. 2021 03 09; 54(3):586-602.e8.
-
Preclinical Studies of the Off-Target Reactivity of AFP158-Specific TCR Engineered T Cells. Front Immunol. 2020; 11:607.
-
Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia. 2020 06; 34(6):1626-1636.